Connect with us

Technology

3D Printing Medical Devices Market size is set to grow by USD 7.07 billion from 2024-2028, Increased demand for personalized or customized medical devices boost the market, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global 3D printing medical devices market size is estimated to grow by USD 7.07 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 25.2%  during the forecast period. Increased demand for personalized or customized medical devices is driving market growth, with a trend towards rising focus on the research for the use of 3D printing process to manufacture living organs and cell structures. However, high initial setup cost of 3d printing facility  poses a challenge. Key market players include 3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

3D Printing Medical Devices Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 25.2%

Market growth 2024-2028

USD 7079.6 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

19.78

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Germany, UK, Japan, and China

Key companies profiled

3D Systems Corp., Anatomics Pty Ltd., Autodesk Inc., Biomerics LLC, Boston Scientific Corp., Desktop Metal Inc., EOS GmbH, Exail Technologies, Formlabs Inc., General Electric Co., INTAMSYS TECHNOLOGY CO. LTD., MATERIALISE NV, Mecuris GmbH, Medtronic Plc, Organovo Holdings Inc., Qualtech Consulting Corp., Renishaw Plc, Schultheiss GmbH, SLM Solutions Group AG, and Stratasys Ltd.

Market Driver

The 3D printing of medical devices, specifically in the field of bioprinting, represents a significant advancement in healthcare technology. This process involves the precise layering of cells, biologic scaffolds, and growth factors to create bioidentical tissue, such as stem cells, skin grafts, and bone and cartilage. Unlike traditional 3D printers that use plastic or metals as raw materials, 3D bioprinters utilize a computer-guided pipette to layer living cells, referred to as bioink, to create artificial living tissues. One of the most promising applications of 3D bioprinting is in organ replacement. This technology holds the potential to address the organ donor shortage and reduce rejections by creating organs that better meet the requirements of the body. For instance, 3D printed bone features a micropore surface that allows osteocytes to adhere, join, and heal better than traditional metal implants. ORGANOVO, a biotechnology company, is pioneering the use of 3D bioprinting to develop in vivo liver tissues for treating rare, life-threatening diseases. Their product, the ExVive 3D Bioprinted Human Liver Tissues, can be used for drug exposure and metabolism studies, offering a valuable alternative to organ transplantation. Allevi and SHIBUYA are among the companies leading the way in 3D bioprinting technology. Allevi introduced the first desktop 3D bioprinter capable of printing living tissues using human cells, while SHIBUYA’s 3D bioprinter is the first cell culture system for building complex cell-based structures. The potential of 3D bioprinting is driving increased R&D efforts in developing devices for this technology. As technological advances continue, 3D printing medical devices are expected to see widespread adoption, fueling the growth of the global 3D printing medical devices market. 

The 3D Printing Medical Devices market is experiencing significant growth due to its ability to produce customized, patient-specific solutions for various medical applications. Stereolithography (SLA) and digital light processing are popular 3D printing technologies used in creating prosthetics implants, orthopedic implants, and wearable medical devices. Dentistry and orthodontics also benefit from 3D printing, with applications including dentures, bone scaffolds, and hearing aids. Tissue-engineered products, remote patient monitoring, telemedicine, and vital signs monitoring are other areas where 3D printing is making an impact. Complex medical procedures, such as implantable and non-implantable medical devices, drug testing, and organ and tissue production, are also being revolutionized by this technology. Computer-aided manufacturing and design, diagnostic centers, medical institutions, and 3D printing laboratories are embracing 3D printing to provide personalized solutions. Laser beam technology, minimally invasive surgery, and surgical equipment are other areas where 3D printing is making a difference. Patient CAD images are used to create patient-specific models and customized implants, including cranial implants for neurosurgery and human skull repairs. Overall, 3D printing is transforming the medical industry by enabling the production of customized, high-quality medical devices in a layer-wise manner. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

The 3D printing medical devices market faces significant challenges due to high capital costs. Equipment for 3D printing or outsourced print service contracts, advanced software for post-processing, and proprietary raw materials contribute to these costs. Desktop FDM or SLA machines cost less than USD5,000, but high-end additive manufacturing printers range from USD200,000 to USD850,000 or even millions. Skilled personnel and training are also necessary, adding to the expenses. A clinical 3D printing lab requires ancillary staff for printing. Production time, ranging from hours to days, limits its use in mass manufacturing. These factors hinder the widespread adoption of 3D printers, potentially impacting the growth of the market negatively.The 3D printing medical devices market is experiencing significant growth due to the advantages it offers in creating customized solutions for various medical needs. However, there are challenges that need to be addressed. For physicians, the use of 3D-printed medical devices in elective surgical procedures requires careful consideration for complex prosthetic limbs and brain designs. Surgeons prefer titanium alloys for surgical tools, but cancer patients benefit from biocompatible materials as drug contact materials. Hearing aid manufacturers are exploring 3D-printed hearing aid devices using biocompatible materials for personalized solutions. CAD/CAM technology and desktop printers are revolutionizing dental clinics and hospitals, providing dental restoration, surgical planning, and personalized prosthetics. Orthopedic prosthetics and surgical instruments also benefit from 3D printing, improving surgical outcomes, operation time, and reducing post-surgical complications. Mechanical protection for tissues and organs is a promising area for 3D printing, with potential applications in organ transplantation and living cells using biomaterials. However, biosafety concerns and ethical issues surrounding the use of human cells and tissues need to be addressed by regulatory bodies like the Human Tissue Authority. Photopolymerization and Medical device manufacturers are using rapid prototyping to innovate, while healthcare professionals embrace the technology for prosthetics, surgical instruments, personalized prosthetics, orthotics, surgeon comfort, and fatigue prevention.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This 3d printing medical devices market report extensively covers market segmentation by  

Application 1.1 Orthopedic and spinal1.2 Dental1.3 Hearing aids1.4 OthersEnd-user 2.1 Hospitals and clinics2.2 Academic institutes2.3 Pharma and biotech companies2.4 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Orthopedic and spinal-  The 3D printing medical devices market encompasses the production of orthopedic and spinal implants using 3D printing technology. This technology enables the fabrication of standard-sized implants, patient-matched implants, and custom implants for individuals with deformities. Hospitals and ambulatory surgery centers are major end-users, as 3D printing allows for the creation of complex structures and individualized implants. Orthopedic and spinal applications dominate the market due to the rising prevalence of related disorders, increasing demand for personalized implants, and the need for advanced surfaces and structures. The technology’s ability to manufacture lattice structures and porous surfaces promotes bone ingrowth and improves implant stability. Titanium implants, commonly used in orthopedics, benefit from 3D printing’s ability to create greater porosity, enhancing bony ingrowth and improving implant stability. In the field of prosthetics, 3D printing significantly reduces manufacturing time and costs while maintaining functionality. The technology’s affordability makes it particularly suitable for children who quickly outgrow their prosthetic limbs. Vendors are increasing investments in R&D to develop advanced orthopedic and spinal implants, further fueling market growth. Key factors driving the market include the aging population, increasing prevalence of orthopedic and spinal disorders, and the demand for customized implants. These factors are expected to propel the growth of the global 3D printing medical devices market during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products, including implants, hearing aids, bone scaffolds, surgical equipment, and more. The process begins with the creation of patient CAD images, which are then used to manufacture standard implants or personalized prosthetics, surgical instruments, and orthotics. The benefits of 3D printing in medical devices extend beyond patient comfort, as it also allows for the production of implantable and non-implantable medical devices using biomaterials, as well as drug testing and potential applications in organ transplantation and tissue engineering. Rapid prototyping and computer-aided manufacturing are key technologies driving the growth of this market, with healthcare professionals and medical device manufacturers embracing the technology to improve patient outcomes and surgical procedures.

Market Research Overview

The 3D printing medical devices market is revolutionizing the healthcare industry by enabling the production of customized medical products in a layer-wise manner using CAD images. This technology allows for the creation of patient-specific products such as implants, hearing aids, bone scaffolds, surgical equipment, and more. The use of patient CAD images ensures a perfect fit and optimal surgical outcomes, reducing operation time and post-surgical complications. 3D printing technology is being applied in various medical fields, including neurosurgery, orthopedics, and dentistry. For instance, it is used to create cranial implants, patient-specific models, and surgical tools for complex procedures. The use of biocompatible materials, such as titanium alloys and photopolymers, ensures the safety and effectiveness of 3D-printed medical devices. The market for 3D-printed medical devices is vast and diverse, encompassing elective surgical procedures, complex prosthetic limbs, brain designs, surgical instruments, and more. The technology is also being used in tissue engineering and organ transplantation, with the potential to print living cells and biomaterials. However, the use of 3D printing in medicine raises biosafety concerns and ethical issues, particularly with regard to the Human Tissue Authority and patient privacy. Medical device manufacturers are working to address these challenges through the use of CAD/CAM technology, rapid prototyping, and collaboration with healthcare professionals. The market for 3D-printed medical devices includes hearing aid manufacturers, dental clinics, hospitals, and surgical planning centers. The technology is also being used to create implantable and non-implantable medical devices, wearable medical devices, and diagnostic tools. The potential applications of 3D printing in medicine are vast, from surgical planning and dental restoration to remote patient monitoring and telemedicine. The future of medicine is undoubtedly 3D printed.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationOrthopedic And SpinalDentalHearing AidsOthersEnd-userHospitals And ClinicsAcademic InstitutesPharma And Biotech CompaniesOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/3d-printing-medical-devices-market-size-is-set-to-grow-by-usd-7-07-billion-from-2024-2028–increased-demand-for-personalized-or-customized-medical-devices-boost-the-market-technavio-302209578.html

SOURCE Infiniti Research, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Avathon Partners with CP PLUS, Largest CCTV Manufacturer in India, to Enhance Public Safety while Strengthening Community Bonds

Published

on

By

PLEASANTON, Calif., Nov. 13, 2024 /PRNewswire/ — Avathon, provider of the leading AI platform for industrial operations, has partnered with CP PLUS, one of the largest manufacturers of CCTV cameras, to create safer, more connected societies by bundling Avathon’s computer vision technology with each camera. The companies are bringing Avathon’s computer vision AI capabilities to small and medium-sized businesses (SMBs) across India, turning their cameras into intelligent assets that enable more secure workplaces, factories and facilities.           

In today’s fast-paced world, it’s hard to keep an eye on every single detail, every minute of the day. Computer vision AI technology gives users the freedom and control to go about their daily lives knowing they will receive proactive alerts identifying safety and security issues in real time.

“Increasing demand for advanced public safety tools, smart home devices and integrated AI-powered cameras is fueling massive industry growth,” said Aditya Khemka, Managing Director, CP PLUS, a subsidiary of Aditya Group. “Our partnership with Avathon will help us to better deliver state-of-the-art AI-powered solutions that feature advanced functions like real-time anomaly detection and intelligent monitoring.”

Avathon’s computer vision AI automatically detects and alerts unsafe conditions and incidents in real time, allowing users to proactively take the right actions. Avathon enables business owners using valuable resources to monitor CCTV camera feeds to get back to focusing on operations. The company partners with OEM camera manufacturers by providing AI technology that enables end customers to quickly and accurately address processes, behaviors, and conditions that cause unacceptable risk. Through its partnership with CP PLUS, Avathon has democratized this technology, giving access to large organizations and small businesses alike.

CP PLUS is India’s leading surveillance brand with the most extensive portfolio in the entire global industry. Representing a major share of the Indian CCTV market, CP PLUS offers a range of products and services to meet the varied needs of government, commercial, residential, and industrial customers and its products are successfully deployed in every nook and corner of India and many countries across verticals and industry.

“AI cameras are paving the path forward in India toward smart-city initiatives and enhanced public safety improvements. In this sometimes disconnected world, it’s comforting to rely on a technology that instantly alerts users to potential dangers and other anomalies,” said Pervinder Johar, CEO of Avathon. “We’re proud to partner with CP PLUS to provide the AI innovations needed to push India to the leading edge of technological advancement.”

About Avathon

Avathon, a leader in Industrial AI, extends the life of critical infrastructure while advancing the journey toward full autonomy. Avathon’s Industrial AI platform empowers commercial and government customers with scalable, secure, and value-driven solutions that enhance efficiency and resilience across heavy industry.

Media contact:

Jon Ross
Sr. PR & Communications Manager
Avathon
jross@avathon.com

View original content:https://www.prnewswire.com/news-releases/avathon-partners-with-cp-plus-largest-cctv-manufacturer-in-india-to-enhance-public-safety-while-strengthening-community-bonds-302304865.html

SOURCE Avathon

Continue Reading

Technology

Belgian Unicorn Odoo Celebrates Remarkable First Anniversary in Indonesia

Published

on

By

JAKARTA, Indonesia, Nov. 14, 2024 /PRNewswire/ — This November, Belgian business management software company Odoo celebrates 1st anniversary of the Indonesian office with esteemed partners and customers like Ismaya, Pertamina Energy Terminal, DORÉ, Dekoruma, Abuba Steak, Perum Bulog and Arista Group, to name a few.

With a mission to help more businesses to become digitally organized, the software company started actively developing the Indonesian market five years ago and has reached record-breaking milestones one after another—91.2% average annual growth and a quadrupled 189 active local partners—making Indonesia the best-performing market in APAC for six consecutive years.

The now locally based Odoo Indonesia is confident in extending services and helping businesses of all sizes in the country to digitally transform business management to contribute to optimized workflow efficiency and national economic growth.

To support rapid market expansion, Odoo will base its operations in BSD as the area embodies the start-up environment the Belgian firm always strives for—vibrant & dynamic—a choice affirmed by its sustained success in digital transformation endeavors across Indonesia.

Odoo opens first SEA office in BSD.

From a squad of 3, Odoo Indonesia has expanded into an over 80-strong team. In 2024, it engaged the community at 41 events in major cities, including Medan, Bandung, Surabaya, and Makassar, and around the archipelago in Java, Sumatra, Kalimantan, and Sulawesi, providing countless on-site support. Within a year of opening, the company introduced multiple landmark integrations and regionalized upgrades.

Odoo-Xendit Integration

Integration with Indonesian-based payment solution provider Xendit is made standard in Odoo to facilitate effortless transactions in Indonesia and across Southeast Asia through QRIS, e-Wallets, convenience stores, and other major payment methods in the region.

e-Faktur Submission

To support the Tax Office e-Faktur application, Odoo now collects necessary data to automate documents to assist users in completing the submission process in compliance with local regulations and is in the last stages of integrating with Pajak.io for direct submission from Odoo.

QRIS Features

The team introduced QRIS into the system to maximize ways to receive payments, facilitating a more convenient and localized payment process for Indonesian Odoo users.

Odoo-Shopee Integration

In October, Odoo announced upcoming integration with Shopee, the leading eCommerce platform in Southeast Asia.

“The opening of Odoo’s new office in BSD marks a significant milestone in our effort to penetrate the Indonesia market. Looking at our journey so far, I am also extremely proud of my team for their relentless contributions in helping our customers become more efficient, one app at a time. Moving forward, we aim to expand the team even more and the best part is: we are always looking for top talents to join us!”  — Benny Putra Sugito, Director of Odoo (Indonesia)

Odoo is committed to leading the Indonesian business scene. While its expansion also aims to generate employment opportunities to offer the country a professional workforce in tech and business management, Odoo is resolute in educating the market about the significance of utilizing the right business tools and is dedicated to offering a comprehensive and integrable yet approachable solution to facilitate an easy digital transformation process for 64.2 million businesses of all sizes in Indonesia.

About Odoo

Odoo is a Belgian online business management software with a complete suite of business modules. The open-source service provider operates in 19 locations worldwide, including Indonesia, the United States, Hong Kong SAR, and Dubai. With 80+ official apps and 49k+ third-party apps, Odoo manages businesses’ finance, sales, inventory & manufacturing processes, human resources, marketing, team productivity, and more.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/belgian-unicorn-odoo-celebrates-remarkable-first-anniversary-in-indonesia-302305086.html

SOURCE PT Odoo Software Indonesia

Continue Reading

Technology

ZEEKR Reports Third Quarter 2024 Unaudited Financial Results

Published

on

By

HANGZHOU, China, Nov. 14, 2024 /PRNewswire/ — ZEEKR Intelligent Technology Holding Limited (“ZEEKR” or the “Company”) (NYSE: ZK), a global premium electric mobility technology company, today announced its unaudited financial results for the third quarter ended September 30, 2024.

Operating Highlights for the Third Quarter of 2024

Total vehicle deliveries were 55,003 units for the third quarter of 2024, representing a 51% year-over-year increase.

Deliveries

2024 Q3

2024 Q2

2024 Q1

2023 Q4

55,003

54,811

33,059

39,657

Deliveries

2023 Q3

2023 Q2

2023 Q1

2022 Q4

36,395

27,399

15,234

32,467

Financial Highlights for the Third Quarter of 2024

Vehicle sales were RMB14,401.3 million (US$2,052.2 million)[1] for the third quarter of 2024, representing an increase of 42.0% from the third quarter of 2023 and an increase of 7.2% from the second quarter of 2024.

Vehicle margin[2] was 15.7% for the third quarter of 2024, compared with 18.1% for the third quarter of 2023 and 14.2% for the second quarter of 2024.

Total revenues were RMB18,358.0 million (US$2,616.0 million) for the third quarter of 2024, representing an increase of 30.7% from the third quarter of 2023 and a decrease of 8.4% from the second quarter of 2024.

Gross profit was RMB2,941.8 million (US$419.2 million) for the third quarter of 2024, representing an increase of 28.5% from the third quarter of 2023 and a decrease of 14.7% from the second quarter of 2024.

Gross margin was 16.0% for the third quarter of 2024, compared with 16.3% for the third quarter of 2023 and 17.2% for the second quarter of 2024.

Loss from operations was RMB1,216.4 million (US$173.3 million) for the third quarter of 2024, representing a decrease of 19.3% from the third quarter of 2023 and a decrease of 29.3% from the second quarter of 2024. Excluding share-based compensation expenses, adjusted loss from operations (non-GAAP)[3] was RMB1,169.8 million (US$166.7 million) for the third quarter of 2024, representing a decrease of 20.8% from the third quarter of 2023 and an increase of 50.5% from the second quarter of 2024.

Net loss was RMB1,139.1 million (US$162.3 million) for the third quarter of 2024, representing a decrease of 21.7% from the third quarter of 2023 and a decrease of 37.0% from the second quarter of 2024. Excluding share-based compensation expenses, adjusted net loss (non-GAAP) was RMB1,092.6 million (US$155.7 million) for the third quarter of 2024, representing a decrease of 23.4% from the third quarter of 2023 and an increase of 26.3% from the second quarter of 2024.

[1] All conversions from Renminbi(“RMB”) to U.S. dollars (“US$”) are made at an exchange rate of RMB7.0176 to US$1.00, set forth in the H.10 statistical release of the Federal Reserve Board on September 30, 2024.

[2] Vehicle margin is the margin of vehicle sales, which is calculated based on revenues and cost of revenues derived from vehicle sales only.

[3] The Company’s non-GAAP financial measures exclude share-based compensation expenses. See “Unaudited Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this announcement.

Key Financial Results

(in RMB millions, except for percentages)

2024 Q3

2024 Q2

2023 Q3

% Change i 

YoY

QoQ

Vehicle sales

14,401.3

13,438.2

10,143.7

42.0 %

7.2 %

Vehicle margin

15.7 %

14.2 %

18.1 %

(2.4)pts

1.5pts

Total revenues

18,358.0

20,040.1

14,044.6

30.7 %

(8.4) %

Gross profit

2,941.8

3,449.8

2,289.4

28.5 %

(14.7) %

Gross margin

16.0 %

17.2 %

16.3 %

(0.3)pts

(1.2)pts

Loss from operations

(1,216.4)

(1,721.0)

(1,507.8)

(19.3) %

(29.3) %

Non-GAAP loss from operations     

(1,169.8)

(777.1)

(1,477.6)

(20.8) %

50.5 %

Net loss

(1,139.1)

(1,808.8)

(1,455.7)

(21.7) %

(37.0) %

Non-GAAP net loss

(1,092.6)

(864.9)

(1,425.6)

(23.4) %

26.3 %

i 

Except for vehicle margin and gross margin, absolute changes instead of percentage changes are presented.

Recent Developments

Delivery Update  

In October 2024, the Company delivered 25,049 vehicles, representing an increase of 92% from October 2023.

New Model Launches

On October 23, 2024, ZEEKR officially launched and commenced deliveries of the ZEEKR MIX, a five-seat, family-oriented vehicle. The ZEEKR MIX redefines the concept of an everyday driver, seamlessly combining ample space, outstanding safety, and agile handling. As the first model built on the Company’s SEA-M architecture, the ZEEKR MIX boasts up to 93% in-cabin space utilization, maximizing interior space through innovative packaging and a capsule-style exterior. Two front-row seats that can swivel 270 degrees and a movable central console enhance cabin versatility, enabling “9+N” cabin scenario modes and flexible seating arrangements.

CEO and CFO Comments

“Our performance remained strong and resilient this quarter, marked by record-high deliveries and successful new model launches,” said Mr. Andy An, ZEEKR’s chief executive officer. “In the third quarter, we set a new record with 55,003 vehicle deliveries, representing a 51% year-over-year increase, and reached an additional milestone in October with monthly deliveries of 25,049 units. Notably, the ZEEKR 7X’s deliveries exceeded 20,000 units within 50 days since its launch, marking a robust achievement in the highly competitive mainstream SUV market. As we expand our product lineup and strengthen each model’s position in its respective category, we are delivering ZEEKR’s ultimate driving experience to more users, further cementing ZEEKR’s industry leadership.”

Mr. Jing Yuan, ZEEKR’s chief financial officer, added, “Our disciplined cost control measures, coupled with ongoing optimization of product structure, economies of scale, and technological innovation, drove a 30.7% year-over-year increase in revenue. Vehicle sales for the quarter grew by 42.0% and 7.2% year-over-year and quarter-over-quarter, respectively. Meanwhile, vehicle margin remained on an upward trajectory, rising to 15.7% in the third quarter of 2024, highlighting our consistent progress in profitability enhancement. Looking ahead, we will continue to consolidate resources, strengthen product capabilities, and expand our industry presence to propel our sustainable growth.”

Financial Results for the Third Quarter of 2024

Revenues

Total revenues were RMB18,358.0 million (US$2,616.0 million) for the third quarter of 2024, representing an increase of 30.7% from RMB14,044.6 million for the third quarter of 2023 and a decrease of 8.4% from RMB20,040.1 million for the second quarter of 2024.

Revenues from vehicle sales were RMB14,401.3 million (US$2,052.2 million) for the third quarter of 2024, representing an increase of 42.0% from RMB10,143.7 million for the third quarter of 2023, and an increase of 7.2% from RMB13,438.2 million for the second quarter of 2024. The year-over-year increase was due to the increase in new product delivery volume, partially offset by the lower average selling price due to the different product mix and pricing strategy changes between the two quarters. The quarter-over-quarter increase was mainly attributable to the launch of the ZEEKR 7X new model in the third quarter of 2024 and the higher average selling price resulting from changes in product mix.

Revenues from sales of batteries and other components were RMB3,245.3 million (US$462.5 million) for the third quarter of 2024, representing a decrease of 1.3% from RMB3,288.8 million for the third quarter of 2023 and a decrease of 38.8% from RMB5,299.2 million for the second quarter of 2024. The revenues from sales of batteries and other components remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly driven by lower sales volume of battery packs in the domestic market.

Revenues from research and development service and other services were RMB711.4 million (US$101.4 million) for the third quarter of 2024, representing an increase of 16.2% from RMB612.1 million for the third quarter of 2023 and a decrease of 45.4% from RMB1,302.6 million for the second quarter of 2024. The year-over-year increase was mainly due to the increased sales of after-sales vehicle services. The quarter-over-quarter decrease was mainly due to the decreased sales of research and development services to related parties.

Cost of Revenues and Gross Margin

Cost of revenues was RMB15,416.2 million (US$2,196.8 million) for the third quarter of 2024, representing an increase of 31.1% from RMB11,755.2 million for the third quarter of 2023 and a decrease of 7.1% from RMB16,590.2 million for the second quarter of 2024. The year-over-year increase was mainly attributable to the increase in vehicle delivery volume and the quarter-over-quarter decrease was mainly attributable to the decrease in sales of batteries and other components.

Gross profit was RMB2,941.8 million (US$419.2 million) for the third quarter of 2024, representing an increase of 28.5% from RMB2,289.4 million for the third quarter of 2023 and a decrease of 14.7% from RMB3,449.8 million for the second quarter of 2024.

Gross margin was 16.0% for the third quarter of 2024, compared with 16.3% for the third quarter of 2023 and 17.2% for the second quarter of 2024. The gross margin remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly attributable to the decreased margins on batteries and other components.

Vehicle margin was 15.7% for the third quarter of 2024, compared with 18.1% for the third quarter of 2023 and 14.2% for the second quarter of 2024. The year-over-year decrease was primarily attributed to the lower average selling price of ZEEKR vehicles due to the different product mix and pricing strategy changes between the two quarters, partially offset by the procurement savings as the cost of auto parts and materials decreased. The quarter-over-quarter increase was mainly due to the change in product mix.

Operating Expenses

Research and development expenses were RMB1,966.2 million (US$280.2 million) for the third quarter of 2024, representing a decrease of 2.6% from RMB2,018.1 million for the third quarter of 2023 and a decrease of 25.1% from RMB2,623.5 million for the second quarter of 2024. Research and development expenses remained relatively stable compared with the third quarter of 2023. The quarter-over-quarter decrease was mainly due to a one-off, large quantity of share-based compensation expenses in the second quarter, conditioned on the Company’s initial public offering.

Selling, general and administrative expenses were RMB2,274.8 million (US$324.1 million) for the third quarter of 2024, representing an increase of 25.4% from RMB1,813.9 million for the third quarter of 2023 and a decrease of 12.7% from RMB2,604.7 million for the second quarter of 2024. The year-over-year increase was mainly due to increased expenses related to the expansion of offline channels in China and overseas as well as the marketing activities of the launch of new models. The quarter-over-quarter decrease was mainly due to a one-off, large quantity of share-based compensation expenses in the second quarter, conditioned on the Company’s initial public offering.

Loss from Operations

Loss from operations was RMB1,216.4 million (US$173.3 million) for the third quarter of 2024, representing a decrease of 19.3% from RMB1.507.8 million for the third quarter of 2023 and a decrease of 29.3% from RMB1,721.0 million for the second quarter of 2024.

Non-GAAP loss from operations, which excludes share-based compensation expenses from loss from operations, was RMB1,169.8 million (US$166.7 million) for the third quarter of 2024, representing a decrease of 20.8% from RMB1,477.6 million for the third quarter of 2023 and an increase of 50.5% from RMB777.1 million for the second quarter of 2024.

Net Loss and Net Loss Per Share

Net loss was RMB1,139.1 million (US$162.3 million) for the third quarter of 2024, representing a decrease of 21.7% from RMB1,455.7 million for the third quarter of 2023 and a decrease of 37.0% from RMB1,808.8 million for the second quarter of 2024.

Non-GAAP net loss, which excludes share-based compensation expenses from net loss, was RMB1,092.6 million (US$155.7 million) for the third quarter of 2024, representing a decrease of 23.4% from RMB1,425.6 million for the third quarter of 2023 and an increase of 26.3% from RMB864.9 million for the second quarter of 2024.

Net loss attributable to ordinary shareholders of ZEEKR was RMB1,226.3 million (US$174.7 million) for the third quarter of 2024, representing a decrease of 16.9% from RMB1,476.1 million for the third quarter of 2023 and a decrease of 44.0% from RMB2,190.2 million for the second quarter of 2024.

Non-GAAP net loss attributable to ordinary shareholders of ZEEKR, which excludes share-based compensation expenses from net loss attributable to ordinary shareholders, was RMB1,179.7 million (US$168.1 million) for the third quarter of 2024, representing a decrease of 18.4% from RMB1,445.9 million for the third quarter of 2023 and a decrease of 5.3% from RMB1,246.3 million for the second quarter of 2024.

Basic and diluted net loss per share attributed to ordinary shareholders were RMB0.48 (US$0.07) each for the third quarter of 2024, compared with RMB0.74 each for the third quarter of 2023 and RMB0.95 each for the second quarter of 2024.

Non-GAAP basic and diluted net loss per share attributed to ordinary shareholders were both RMB0.46 (US$0.07) each for the third quarter of 2024, compared with RMB0.72 each for the third quarter of 2023 and RMB0.54 each for the second quarter of 2024.

Basic and diluted net loss per American Depositary Share (“ADS[4]”) attributed to ordinary shareholders were RMB4.80 (US$0.68) each for the third quarter of 2024, compared with RMB9.51 each for the second quarter of 2024.

Non-GAAP basic and diluted net loss per ADS attributed to ordinary shareholders were RMB4.62 (US$0.66) each for the third quarter of 2024, compared with RMB5.41 each for the second quarter of 2024.

[4] Each ADS represents ten ordinary shares.

Balance Sheets

Cash and cash equivalents and restricted cash was RMB8,297.7 million (US$1,182.4 million) as of September 30, 2024.

Conference Call

The Company’s management will host an earnings conference call on Thursday, November 14, 2024, at 7:00 A.M. U.S. Eastern Time (8:00 P.M. Beijing/Hong Kong Time on the same day).

All participants who wish to join the call are requested to complete the online registration using the link provided below. After registration, each participant will receive by email a set of dial-in numbers, a passcode and a unique access PIN to join the conference call. Participants may pre-register at any time, including up to and after the call start time.

Participant Online Registration: https://dpregister.com/sreg/10194063/fdd5d5735e

A live webcast of the conference call will be available on the Company’s investor relations website at https://ir.zeekrlife.com/.

About ZEEKR

ZEEKR (NYSE: ZK) is a global premium electric mobility technology brand from Geely Holding Group. ZEEKR aims to create a fully integrated user ecosystem with innovation as a standard. ZEEKR utilizes Sustainable Experience Architecture (SEA) and develops its own battery technologies, battery management systems, electric motor technologies, and electric vehicle supply chains. ZEEKR’s value is equality, diversity, and sustainability. Its ambition is to become a true mobility solution provider.

ZEEKR operates its R&D centers and design studios in Ningbo, Hangzhou, Gothenburg, and Shanghai and boasts state-of-the-art facilities and world-class expertise. Since ZEEKR began delivering vehicles in October 2021, the brand has developed a diversified product portfolio that primarily includes the ZEEKR 001, a luxury shooting brake; the ZEEKR 001 FR, a hyper-performing electric shooting brake; the ZEEKR 009, a pure electric luxury MPV; the ZEEKR 009 Grand, a four-seat ultra-luxury flagship MPV; the ZEEKR X, a compact SUV; the ZEEKR 7X, a premium electric five-seater SUV; the ZEEKR MIX; and an upscale sedan model. ZEEKR has announced plans to sell vehicles in global markets, and has an ambitious roll-out plan over the next 5 years to satisfy the rapidly expanding global EV demand.

For more information, please visit https://ir.zeekrlife.com/.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, non-GAAP basic and diluted net loss per ordinary share attributed to ordinary shareholders, non-GAAP basic and diluted net loss per ADS attributed to ordinary shareholders, in evaluating its operating results and for financial and operational decision-making purposes. By excluding the impact of share-based compensation expenses, the Company believes that the non-GAAP financial measures help identify underlying trends in its business and enhance the overall understanding of the Company’s past performance and future prospects. The Company also believes that the non-GAAP financial measures allow for greater visibility with respect to key metrics used by the Company’s management in its financial and operational decision-making. The non-GAAP financial measures are not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measures have limitations as analytical tools and when assessing the Company’s operating performance, investors should not consider them in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company’s performance.

For more information on the non-GAAP financial measures, please see the table captioned “Unaudited Reconciliations of GAAP and non-GAAP Results” set forth in this announcement.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.0176 to US$1.00, the exchange rate on September 30, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred to could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “future,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC. All information provided in this announcement is as of the date of this announcement, and the Company does not undertake any duty to update such information, except as required under applicable law.

For Investor Enquiries
ZEEKR
Investor Relations
Email: ir@zeekrlife.com

For Media Enquiries
ZEEKR
Media Relations
Email: Globalcomms@zeekrlife.com

 

ZEEKR INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands)

As of

December 31

September 30

September 30

2023

2024

2024

RMB

RMB

US$

ASSETS

Current assets:

Cash and cash equivalents

3,260,670

5,640,993

803,835

Restricted cash

844,079

2,656,734

378,582

Notes receivable

487,851

952,108

135,674

Accounts receivable

1,104,450

2,096,355

298,728

Inventories

5,228,689

4,745,085

676,169

Amounts due from related parties

7,256,861

6,535,623

931,319

Prepayments and other current assets    

2,294,508

2,711,024

386,317

Total current assets

20,477,108

25,337,922

3,610,624

Property, plant and equipment, net

2,914,274

3,265,370

465,312

Intangible assets, net

410,912

624,404

88,977

Land use rights, net

51,755

62,185

8,861

Operating lease right-of-use assets

2,443,545

2,225,175

317,085

Deferred tax assets

86,395

195,175

27,812

Long-term investments

459,794

629,383

89,686

Other non-current assets

273,717

367,752

52,404

Total non-current assets

6,640,392

7,369,444

1,050,137

TOTAL ASSETS

27,117,500

32,707,366

4,660,761

 

ZEEKR INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)

(Amounts in thousands)

As of

December 31

September 30

September 30

2023

2024

2024

RMB

RMB

US$

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Short-term Borrowings

30,000

4,275

Accounts payable

4,104,717

3,589,418

511,488

Notes payable

5,504,945

12,474,151

1,777,552

Amounts due to related parties

16,355,902

15,008,230

2,138,656

Income tax payable

108,083

172,826

24,628

Accruals and other current liabilities

6,243,956

8,114,841

1,156,354

Total current liabilities

32,317,603

39,389,466

5,612,953

Long-term borrowings

414,630

59,084

Operating lease liabilities, non-current

1,807,159

1,577,950

224,856

Amounts due to related parties, non-current

1,100,000

Other non-current liabilities

563,001

540,082

76,961

Deferred tax liability

8,337

8,224

1,172

Total non-current liabilities

3,478,497

2,540,886

362,073

TOTAL LIABILITIES

35,796,100

41,930,352

5,975,026

SHAREHOLDERS’ EQUITY

Ordinary shares

2,584

3,361

479

Convertible preferred shares

362

Shares subscription receivable

(66)

(9)

Additional paid-in capital

11,213,798

15,683,094

2,234,823

Accumulated deficits

(20,865,686)

(26,296,475)

(3,747,218)

Accumulated other comprehensive income/(loss)     

17,555

(26,402)

(3,762)

Total ZEEKR shareholders’ deficit

(9,631,387)

(10,636,488)

(1,515,687)

Non-controlling interest

952,787

1,413,502

201,422

TOTAL SHAREHOLDERS’ DEFICIT

(8,678,600)

(9,222,986)

(1,314,265)

TOTAL LIABILITIES AND SHAREHOLDERS’
EQUITY

27,117,500

32,707,366

4,660,761

 

ZEEKR INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
(LOSS)/INCOME

(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)

Three Months Ended

September 30

June 30

September 30

September 30

2023

2024

2024

2024

RMB

RMB

RMB

US$

Revenues:

Vehicle sales

10,143,742

13,438,241

14,401,309

2,052,170

Sales of batteries and other components     

3,288,766

5,299,171

3,245,331

462,456

Research and development service and
other services

612,103

1,302,639

711,362

101,368

Total revenues

14,044,611

20,040,051

18,358,002

2,615,994

Cost of revenues:

Vehicle sales

(8,308,327)

(11,533,020)

(12,146,781)

(1,730,902)

Sales of batteries and other components

(3,050,588)

(4,223,452)

(2,808,646)

(400,229)

Research and development service and
other services

(396,289)

(833,756)

(460,775)

(65,660)

Total cost of revenues

(11,755,204)

(16,590,228)

(15,416,202)

(2,196,791)

Gross profit

2,289,407

3,449,823

2,941,800

419,203

Operating expenses:

Research and development expenses

(2,018,136)

(2,623,471)

(1,966,167)

(280,177)

Selling, general and administrative
expenses

(1,813,890)

(2,604,665)

(2,274,751)

(324,149)

Other operating income, net

34,851

57,287

82,747

11,791

Total operating expenses

(3,797,175)

(5,170,849)

(4,158,171)

(592,535)

Loss from operations

(1,507,768)

(1,721,026)

(1,216,371)

(173,332)

Interest expense

(28,186)

(23,396)

(8,088)

(1,153)

Interest income

27,614

42,537

43,255

6,163

Other income/(expense), net

6,020

(7,809)

54,967

7,833

Loss before income tax expense and
share of losses in equity method
investments

(1,502,320)

(1,709,694)

(1,126,237)

(160,489)

Share of income in equity method
investments

33,021

85,852

81,500

11,614

Income tax benefits/(expense)

13,605

(184,980)

(94,409)

(13,453)

Net loss

(1,455,694)

(1,808,822)

(1,139,146)

(162,328)

Less: income attributable to non-
controlling interest

20,368

381,363

87,134

12,416

Net loss attributable to shareholders
of ZEEKR

(1,476,062)

(2,190,185)

(1,226,280)

(174,744)

 

ZEEKR INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
(LOSS)/INCOME (CONTINUED)

(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)

Three Months Ended

September 30

June 30

September 30

September 30

2023

2024

2024

2024

RMB

RMB

RMB

US$

Net loss per share attributed to
ordinary shareholders:

Basic and diluted

(0.74)

(0.95)

(0.48)

(0.07)

Weighted average shares used in
calculating net loss per share:

Basic and diluted

2,000,000,000

2,301,866,887

2,552,901,668

2,552,901,668

Net loss per ADS attributed to
ordinary shareholders:

Basic and diluted

(9.51)

(4.80)

(0.68)

Weighted average ADS used in
calculating net loss per ADS:

Basic and diluted

230,186,689

255,290,167

255,290,167

Net loss

(1,455,694)

(1,808,822)

(1,139,146)

(162,328)

Other comprehensive income/(loss),     
net of tax of nil:

Foreign currency translation
adjustments

(35,240)

74,670

(75,858)

(10,810)

Comprehensive loss

(1,490,934)

(1,734,152)

(1,215,004)

(173,138)

Less: comprehensive income/(loss)
attributable to non-controlling interest

20,368

381,363

87,134

12,416

Comprehensive loss attributable to
shareholders of ZEEKR

(1,511,302)

(2,115,515)

(1,302,138)

(185,554)

 

ZEEKR INC.

UNAUDITED RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS

(Amounts in thousands, except share/ADS and per share/ADS data and otherwise noted)

Three Months Ended

September 30

June 30

September 30

September 30

2023

2024

2024

2024

RMB

RMB

RMB

US$

Loss from operations

(1,507,768)

(1,721,026)

(1,216,371)

(173,332)

Share-based compensation expenses      

30,142

943,921

46,595

6,640

Non-GAAP loss from operations

(1,477,626)

(777,105)

(1,169,776)

(166,692)

Net loss

(1,455,694)

(1,808,822)

(1,139,146)

(162,328)

Share-based compensation expenses

30,142

943,921

46,595

6,640

Non-GAAP net loss

(1,425,552)

(864,901)

(1,092,551)

(155,688)

Net loss attributable to ordinary
shareholders

(1,476,062)

(2,190,185)

(1,226,280)

(174,744)

Share-based compensation expenses

30,142

943,921

46,595

6,640

Non-GAAP net loss attributable to
ordinary shareholders of ZEEKR

(1,445,920)

(1,246,264)

(1,179,685)

(168,104)

Weighted average number of
ordinary shares used in calculating
Non-GAAP net loss per share

Basic and diluted

2,000,000,000

2,301,866,887

2,552,901,668

2,552,901,668

Non-GAAP net loss per ordinary
share attributed to ordinary
shareholders

Basic and diluted

(0.72)

(0.54)

(0.46)

(0.07)

Weighted average number of ADS
used in calculating Non-GAAP net
loss per ADS

Basic and diluted

230,186,689

255,290,167

255,290,167

Non-GAAP net loss per ADS
attributed to ordinary shareholders

Basic and diluted

(5.41)

(4.62)

(0.66)

 

View original content:https://www.prnewswire.com/news-releases/zeekr-reports-third-quarter-2024-unaudited-financial-results-302305084.html

SOURCE ZEEKR Intelligent Technology Holding Limited

Continue Reading

Trending